MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-DL-04-0011090
Cooper Pharma Limited - pharma in Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2024
₹63.28 Cr
▼ 1% YoY
Net profit · FY 2024
₹14.61 Cr
Net margin 23.1%
EBITDA · FY 2024
₹20.4 Cr
EBITDA margin 32.2%
Authorised capital
₹3 Cr
Registered with MCA
Paid-up capital
₹1 Cr
Issued & subscribed
Open charges
₹3.03 Cr
Satisfied ₹22.6 Cr
Company age
37 yrs
Est. 1989
Employees · EPFO
122
Provident fund records
About Cooper Pharma Limited
Data last updated:
Cooper Pharma Limited is a public limited company based in Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 February 1989 and has been in existence for over 37 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24231DL1989PLC034902. The company has 1 GST registration on record, which is no longer active.
The company has an authorised share capital of ₹3 Cr and a paid-up capital of ₹1 Cr. It was formerly known as Cooper Pharma Private Limited. It is led by directors including Rakesh Bhargava (Managing Director) and Abhishek Bhargava (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No. – 5 Nidhi Plaza – II 2nd Floor, L.S.C. Gulabi Bagh, Delhi, India – 110052.
As per the financials filed for FY 2024, the company reported a revenue of ₹63.28 Cr, a decline of 1% compared to the previous year. For the same year it recorded a net profit of ₹14.61 Cr (net margin 23.1%) and EBITDA of ₹20.4 Cr (EBITDA margin 32.2%). Revenue has grown at a compounded annual rate (CAGR) of 13% over three years and 5% over five years.
The company has about 122 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Cooper Pharma. As per MCA filings, the company has open charges of ₹3.03 Cr and satisfied charges of ₹22.6 Cr on record. Court records list 21 cases involving the company, including 8 filed by the company and 13 filed against it; 4 cases are pending. The company has 1 deal on record (1 secondary share transfer); the latest was in January 2009. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Arbro Pharmaceuticals Private Limited with revenue of ₹64.16 Cr. The company has 7 MSME Form 1 returns on record between 2019 and 2024, listing 460 overdue payments to 26 micro and small suppliers.
Cooper Pharma Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-04-0011090). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cooperpharma.com.
Company details
CIN U24231DL1989PLC034902
Registration Number 034902
Incorporation Date 02 February 1989
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-DL-04-0011090
Key People
Rakesh Bhargava Managing Director Abhishek Bhargava Whole-Time Director Dinesh Kumar Director Recognitions & Rankings of Cooper Pharma
Contact details
Cooper Pharma Limited's registered office is in Delhi, Delhi. Its website is cooperpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No. – 5 Nidhi Plaza – II 2nd Floor, L.S.C. Gulabi Bagh, Delhi, India – 110052
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Cooper Pharma Limited, buy the company report.
Comprehensive company report
Cooper Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Cooper Pharma operates one associated brand: Cooper Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures generic pharmaceuticals and exports to over 25 countries. | cooperpharma.com |
Business activity
The main business activity of Cooper Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Cooper Pharma Limited, buy the company report.
Financials of Cooper Pharma Limited
FY 2025 filings availableCooper Pharma Limited reported revenue of ₹63.28 Cr (down 1% YoY) for FY 2024.
Revenue · FY 2024
₹63.28 Cr ▼ 1%
Net profit · FY 2024
₹14.61 Cr margin 23.1%
EBITDA · FY 2024
₹20.4 Cr margin 32.2%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 1%
3 years · compounded
▲ 13%
5 years · compounded
▲ 5%
EBITDA CAGR growth
1 year
▲ 39%
3 years · compounded
▲ 32%
5 years · compounded
▲ 3%
Revenue fell 1% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 5%. EBITDA rose 39% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹63.28 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹20.4 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹14.61 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 32.2% | ||||
| Net Profit Margin | 23.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Cooper Pharma Limited, buy the company report.
Board of directors of Cooper Pharma Limited
Cooper Pharma has 3 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rakesh Bhargava Also directs: Cooper Life Sciences Private Limited, Cooper Biotech Private Limited, DW Customer Support Private Limited and 1 more | Managing Director | 02 Feb 1989 | 37 Years 8 Months | Current |
| Dinesh Kumar | Director | 05 Jun 2024 | 2 Years 4 Months | Current |
| Abhishek Bhargava | Whole-Time Director | 01 Aug 2009 | 17 Years 2 Months | Current |
Peer comparison
Cooper Pharma Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Arbro Pharmaceuticals Private Limited | ₹64.16 Cr (FY 2025) | -9.0% | Delhi, India | |||
| Kilitch Healthcare India Limited | ₹63.63 Cr (FY 2024) | 7.0% | Mumbai, Maharashtra, India | |||
| Sance Laboratories Private Limited | ₹63.45 Cr (FY 2025) | 14.0% | Kottayam, Kerala, India | |||
| Adley Lab Limited | ₹63.38 Cr (FY 2025) | 19.0% | Derabassi, Punjab, India | |||
| Cooper Pharma Limitedthis company | ₹63.28 Cr (FY 2024) | ₹14.61 Cr | 23.1% | -1.0% | 122 | Delhi, India |
| Althea Pharma Private Limited | ₹63.27 Cr (FY 2024) | 14.0% | Vapi, Gujarat, India | |||
| Onyx Biotec Limited | ₹63.12 Cr (FY 2025) | 17.0% | Solan, Himachal Pradesh, India | |||
| Thinq Pharma-Cro Limited | ₹62.89 Cr (FY 2025) | 17.0% | Mumbai, Maharashtra, India | |||
| Preet Remedies Limited | ₹62.83 Cr (FY 2025) | 18.0% | Chandigarh, India |
To see the full peer comparison of Cooper Pharma Limited, buy the company report.
Auditor
Cooper Pharma Limited is audited by P.C BINDAL & CO. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| P.C BINDAL & CO. | FY 2024 | 003824N |
Shareholding
The shareholding of Cooper Pharma Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Cooper Pharma Limited, buy the company report.
Charges & borrowings
Open charges
₹3.03 Cr
Satisfied charges
₹22.6 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Apr 2011 | 10288438 | Punjab National Bank | ₹2.5 Lakh | Open | |
| 28 Mar 2006 | 10002287 | Small Industries Developmnt Bank of India | ₹3 Cr | Open | |
| 02 Apr 2025 | 101073359 | Others | ₹12.5 Cr | Satisfied | |
| 04 Jul 2018 | 100232370 | Others | ₹9.9 Lakh | Satisfied | |
| 13 Feb 2015 | 10555644 | Dbs Bank Ltd. | ₹5 Cr | Satisfied |
To see the full charge records of Cooper Pharma Limited, buy the company report.
Total charge records: 6 View all charges
Deals & funding
Cooper Pharma Limited has 1 deal on record (1 secondary share transfer); the latest was in January 2009.
Total deals
1
Secondary share transfer
1
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2009 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Cooper Pharma Limited has 21 court cases on record: 8 filed by Cooper Pharma, 13 filed against it. 4 cases are pending and 17 are disposed.
Total cases
21
Filed by the company
8
Filed against the company
13
Pending
4
Disposed
17
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 12 | 7 | 1 |
| High courts | 9 | 6 | 3 |
Cases on record (5 of 21)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Central, Delhi | Commercial suit | Filed by the company against La Renon Healthcare Private Limited | Disposed |
| High Court of Delhi | Commercial suit | Filed against the company by Karan Healthcare Private Limited | Disposed |
| Bombay High Court | Court case (S) | Filed against the company by M/S. Ajanta Pharma Ltd. | Disposed |
| Bombay High Court | Interim or miscellaneous application | Filed against the company by Shalina Laboratories Private Limited | Pending |
| High Court of Punjab and Haryana | Criminal miscellaneous application | Filed by the company against State of Punjab | Pending |
To see the full case history of Cooper Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Cooper Pharma Limited has 7 MSME Form 1 returns on record between 2019 and 2024, listing 460 overdue payments to 26 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 26)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Bhasin Packwell Pvt Ltd | |||
| Mony Chemicals | |||
| an individual supplier | |||
| Alben Chemicals Private Limited |
To see the full MSME payment records of Cooper Pharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Cooper Pharma has 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
1
Associated companies
Employees & EPFO
Cooper Pharma Limited has a workforce of 122 employees on its EPFO records as of Mar 29, 2025, across 1 active EPFO establishment.
Employee count
122
Active EPFO establishments
1
Employee growth
2.52%
GST
Cooper Pharma has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
Total GSTINs
1
Cancelled / inactive
1
To see the full GST registrations and return filing status of Cooper Pharma Limited, buy the company report.
Recent activity
Cooper Pharma Limited has 14 board changes on record since 1989: 3 appointments and 11 cessations. The latest: Dinesh Kumar ceased to be Additional Director on 29 Sep 2024.
AGM
Cooper Pharma Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge registered on 02 Apr 2025 via Charge ID 101073359 with Others was fully satisfied on 15 Sep 2025.
Charges
A charge with Others amounted to Rs. 12.50 Cr with Charge ID 101073359 was registered on 02 Apr 2025.
Filing
Cooper Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi.
Charges
A charge registered on 04 Jul 2018 via Charge ID 100232370 with Others was fully satisfied on 11 Mar 2025.
Ceased
Dinesh Kumar ceased to be Additional Director.
Appointed
Dinesh Kumar was appointed as Director.
Charges
A charge registered on 13 Feb 2015 via Charge ID 10555644 with Dbs Bank Ltd. was fully satisfied on 11 Jan 2022.
Charges
A charge registered on 20 Mar 2007 via Charge ID 10047626 with Punjab National Bank was fully satisfied on 28 Jul 2021.
Ceased
Ravi Kant ceased to be Additional Director.
Ceased
Nagendra Prasad Bramhadev Upadhyay ceased to be Director.
Ceased
Abhijit Sengupta ceased to be Director.
16 earlier events are in the company report.
Frequently asked questions
Cooper Pharma is an active public limited company based in Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 February 1989 (37+ years old) and is registered under CIN U24231DL1989PLC034902.
Cooper Pharma has 3 current directors:
- Rakesh Bhargava - Managing Director
- Abhishek Bhargava - Whole-Time Director
- Dinesh Kumar - Director
The latest financial statements of Cooper Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
No. Cooper Pharma has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Cooper Pharma is U24231DL1989PLC034902. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Cooper Pharma has 21 court cases on record: 8 filed by the company and 13 filed against it. 4 are pending. Most are in the district courts.
Cooper Pharma was incorporated on 02 February 1989, making it 37+ years old. It is registered with the Registrar of Companies, Delhi.
Cooper Pharma has 1 deal on record (1 secondary share transfer); the latest was in January 2009.
The peers of Cooper Pharma by revenue are Arbro Pharmaceuticals Private Limited, Kilitch Healthcare India Limited, Sance Laboratories Private Limited, Adley Lab Limited, Althea Pharma Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Dinesh Kumar ceased to be Additional Director on 29 Sep 2024. Dinesh Kumar was appointed as Director on 05 Jun 2024. Ravi Kant ceased to be Additional Director on 29 Oct 2020. Cooper Pharma has 14 board changes on record in total.
Yes, Cooper Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-DL-04-0011090).
Cooper Pharma has 7 MSME Form 1 returns on record between 2019 and 2024, listing 460 overdue payments to 26 micro and small suppliers. The latest return was filed on 30 Apr 2024.